Pharma companies Teva and Mylan warned that they are currently experiencing temporary supply disruptions for products Tiagabine and Mianserin respectively.
According to PSNC, Teva, the sole manufacturers of Tiagabine 5mg, 10 mg and 15 mg tablets, have advised a resupply date of end of October 2019. Manufacturers of Mianserin 10mg and 30mg tablets, Mylan, have advised a resupply date of end of 2019.
Both companies, however, said the supplies are available from special importers on an ‘unlicensed’ basis.
If a prescriber wishes a pharmacist to dispense an import, PSNC advises to annotate such prescriptions as ‘specials/unlicensed’ in the prescribing line and endorse as follows:
- Amount dispensed over pack size used;
- Invoice price per pack size from which the order was supplied less any discount or rebate;
- Manufacturers’/importers’ MHRA licence number;
- Batch number of the product supplied;